Proprietary pipeline of next generation immunology and immuno-oncology drugs.

numab graphic numab graphic numab graphic numab graphic

Highlights of tech platform & competitive edge

Using a novel, rational process, our proprietary discovery and engineering technology yields multispecific antibody-based therapeutics with tailored pharmacokinetic properties that improve on first generation antibody therapies in terms of potency, stability, effect duration and safety. Alongside our own in-house pipeline programs we have a number of strong discovery and development partnerships with pharma and biotech.

Latest News
March 05, 2019

Numab announces entry into a license agreement with Intarcia for anti-inflammatory ND016

Pfäffikon, Switzerland, March 5, 2018 – Numab Therapeutics AG…

Pfäffikon, Switzerland, March 5, 2018 – Numab Therapeutics AG today announced that Intarcia Therapeutics Inc. has executed its option to in-license ND016, being developed for the treatment of autoimmune disorders. Numab discovered ND016 on behalf of Intarcia under a previous research and option agreement. Under the present exclusive license agreement, Intarcia receives worldwide rights to develop and commercialize ND016 in exchange for license payments of up to CHF 70 million and up to double digit tiered royalties on net sales.
January 04, 2019

Numab builds out clinical advisory board with high profile appointments

Numab Therapeutics AG, a biopharmaceutical company developing…

Numab Therapeutics AG, a biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer, today announced the appointments of Prof. Mario Sznol from Yale Cancer Center and Prof. David Hong from the MD Anderson Cancer Center to its clinical advisory board. They will join Dr. Ignacio Melero who was appointed in September last.
September 20, 2018

Numab appoints immunotherapy pioneer Ignacio Melero as scientific advisor

Numab Therapeutics AG, a biopharmaceutical company developing…

Numab Therapeutics AG, a biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer, today announced it appointed Dr. Ignacio Javier Melero Bermejo as scientific advisor. Ignacio Melero, M.D., Ph.D., is professor of immunology at the Academic Hospital of Navarra and at the Center for Applied Medical Research (CIMA) of the University of Navarra. He leads a group working in translational tumor immunotherapy with emphasis on cell therapy, cytokine gene therapy, and immune-stimulatory monoclonal antibodies.
More News
Our websites uses Google Analytics and cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our privacy statement.
Accept